Antigen News and Research

RSS

Study demonstrates safety of novel immuno-oncology therapy in patients with advanced solid tumors

A novel therapy designed to help stimulate the body's immune system response against cancer appears to be safe to use as alone or in combination with immune checkpoint inhibitors.

1 Dec 2020

Memory B cells persist in recovered COVID-19 patients

A team of scientists from the University of Washington, USA, and the Karolinska Institute, Sweden, has comprehensively studied the antibody-mediated immune responses in patients diagnosed with coronavirus disease 2019 (COVID-19).

30 Nov 2020

HIV and TB laboratory systems used to scale up COVID-19 testing in Africa

Many countries in resource-limited settings have high HIV, malaria, tuberculosis, hepatitis, and/or sexually transmitted infection (STI) burdens.

30 Nov 2020

Virus induced lymphocytes show promise for COVID-19 and future pandemics

Researchers in the United States have conducted a study demonstrating the potential of a novel therapeutic approach to treating coronavirus disease 2019 (COVID-19). The therapy augments the body’s T cell response to the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by providing a boost of rapidly expanded virus-specific T cells.

30 Nov 2020

Penn study opens the door to let CAR T cells reach the tumor microenvironment

The labyrinth of jumbled blood vessels in the tumor microenvironment remains one of the toughest blockades for cellular therapies to penetrate and treat solid tumors.

30 Nov 2020

Mollusc-derived compounds potential medicines for COVID-19 and other respiratory diseases

A research team has reviewed the existing literature on compounds derived from molluscs used for treating respiratory diseases.

30 Nov 2020

Healthy diet plays vital role in warding off COVID-19

A researcher at the School of Human Development and Health, Faculty of Medicine, University of Southampton, explored nutrition's role in boosting the immune system to combat COVID-19 infection.

29 Nov 2020

MARA project aims to use new DNA based nanotechnology to fight bacteria

Antibiotics are used to prevent and treat bacterial infections. They have played a major role in combating infectious diseases such as tuberculosis, pneumonia, typhoid fever, and meningitis in 20th century.

27 Nov 2020

Siemens Healthineers SARS-CoV-2 IgG antibody test demonstrates ability to detect neutralizing antibodies

Siemens Healthineers has announced its SARS-CoV-2 IgG Antibody Test has proven to measure neutralizing antibodies and has achieved CE Mark. The test is an enhanced version of the assay which became available globally this summer.

From Siemens Healthineers 27 Nov 2020

Combining cell engineering with machine learning to design living medicines for cancer

Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research.

26 Nov 2020

Early interferon therapy may mitigate COVID-19 severity

A recent review of COVID-19 therapies explores the utility of interferons in the battle against severe COVID-19, and concludes that they deserve further development.

26 Nov 2020

Novel CAR T-cell therapy shows promising early results in children with neuroblastoma

A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumors, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer.

25 Nov 2020

Why employers find it so hard to test for COVID

Brandon Hudgins works the main floor at Fleet Feet, a running-shoe store chain, for more than 30 hours a week. He chats with customers, measuring their feet and dashing in and out of the storage area to locate right-sized shoes. Sometimes, clients drag their masks down while speaking. Others refuse to wear masks at all.

25 Nov 2020

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

A study conducted by researchers based in Italy suggests that SARS-CoV-2 induces durable and strong immunity in patients who had moderate to severe COVID-19.

25 Nov 2020

BCG vaccination appears to trigger cross-reactive SARS-CoV-2-specific T cell response

Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.

24 Nov 2020

Mild COVID-19 disease may trigger long-term immunity

Researchers in the United States have conducted a study showing that individuals who have recovered from mild coronavirus disease 2019 (COVID-19) developed sustained protective immune memory against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Nov 2020

The role of micro-RNA in SARS-CoV-2 infection and COVID-19

A team of researchers based in Iran have explored the role of micro-RNA in COVID-19. Their study titled, “The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection,” was published in the latest issue of the journal International Immunopharmacology.

24 Nov 2020

Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test

Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.

From Avacta Life Sciences Ltd. 24 Nov 2020

COVID-19: HLA class I genotypes and mortality

The study, published on the preprint server medRxiv, explores the ability of HLA class I molecules to mediate the outcome in COVID-19 patients.

24 Nov 2020

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

A thought-provoking new study reports that the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies elicited by natural infection may not be able to neutralize emerging strains that display deletion mutations in their genomic RNA.

23 Nov 2020

Antigen News and Research

Study demonstrates safety of novel immuno-oncology therapy in patients with advanced solid tumors

Memory B cells persist in recovered COVID-19 patients

HIV and TB laboratory systems used to scale up COVID-19 testing in Africa

Virus induced lymphocytes show promise for COVID-19 and future pandemics

Penn study opens the door to let CAR T cells reach the tumor microenvironment

Mollusc-derived compounds potential medicines for COVID-19 and other respiratory diseases

Healthy diet plays vital role in warding off COVID-19

MARA project aims to use new DNA based nanotechnology to fight bacteria

Siemens Healthineers SARS-CoV-2 IgG antibody test demonstrates ability to detect neutralizing antibodies

Combining cell engineering with machine learning to design living medicines for cancer

Early interferon therapy may mitigate COVID-19 severity

Novel CAR T-cell therapy shows promising early results in children with neuroblastoma

Why employers find it so hard to test for COVID

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

BCG vaccination appears to trigger cross-reactive SARS-CoV-2-specific T cell response

Mild COVID-19 disease may trigger long-term immunity

The role of micro-RNA in SARS-CoV-2 infection and COVID-19

Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test

COVID-19: HLA class I genotypes and mortality

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics